Patnaik grade II dermal MCTs with mitotic counts near 4 represent which category?

• A. A gray area where beclin-1 testing could help decide on adjunctive therapy
• B. A clearly low-risk tumor
• C. A benign lesion
• D. A high-grade MCT

Answer: (A)

Patnaik grade II dermal mast cell tumors with a mitotic count around four sit in a prognostic middle ground. Grade II tumors are a mixed group, and a mitotic count near 4 per 10 high-power fields isn’t clearly low-risk or clearly high-risk. That ambiguity means histology alone can’t reliably predict behavior, so additional biomarkers can help refine risk and guide treatment decisions after surgery. Beclin-1, linked to autophagy, has been explored as a prognostic marker in canine MCTs; in this gray zone, testing Beclin-1 expression can provide extra information to help decide whether adjunctive therapy is warranted. So this scenario best fits a gray area where Beclin-1 testing could inform management.

For context, a clearly low-risk tumor would typically have more favorable histology and lower mitotic activity; a benign lesion isn’t malignant at all; and a high-grade MCT would usually show more aggressive features with higher mitotic activity and other malignant characteristics.